Outcomes from the International Society of Nephrology Forum on Complement Therapeutics in C3G & IgAN

D Kavanagh; A Alladin-Karan; S Alexander; S Chauvet; C K Cheung; H T Cook; F Fakhouri; V Fremeaux-Bacchi; D P Gale; P Garred; R A Lafayette; A L T Ma; C Nester; R J H Smith; E Pillebout; H N Reich; D V Rizk; I S D Roberts; B H Rovin; S H Sacks; S Shah; H Trimarchi; M Vivarelli; E K S Wong; H Zhang; J Barratt; Forum Participants

doi:10.1016/j.kint.2026.08.007

Back

Outcomes from the International Society of Nephrology Forum on Complement Therapeutics in C3G & IgAN

Journal article

Open access

Peer reviewed

Outcomes from the International Society of Nephrology Forum on Complement Therapeutics in C3G & IgAN

D Kavanagh, A Alladin-Karan, S Alexander, S Chauvet, C K Cheung, H T Cook, F Fakhouri, V Fremeaux-Bacchi, D P Gale, P Garred, …

Kidney international

08/26/2026

DOI: 10.1016/j.kint.2026.08.007

PMID: 42648401

Files and links (1)

url

https://doi.org/10.1016/j.kint.2026.08.007View

Published (Version of record) Open Access

Abstract

C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are both prototypical complement disorders in which complement overactivation is the primary driver of disease. Complement is not the primary cause of disease in IgA nephropathy (IgAN); however, increasing evidence implicates complement as a secondary factor in kidney damage in this more complex, multifactorial disorder. The success of recent clinical trials using alternative pathway complement inhibitors in C3G, IC-MPGN, and IgAN pose questions as to how they should be used in the real world. We report the findings of the 2025 International Society of Nephrology Forum on Complement Therapeutics in C3G & IgAN, where a global panel of experts considered the current state of knowledge, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included how complement biomarkers, complement autoantibodies, genetics and the kidney biopsy guide therapy. The current rationale for the use of complement inhibitors and their place within the current therapeutic landscape are discussed.

Details

Title: Subtitle: Outcomes from the International Society of Nephrology Forum on Complement Therapeutics in C3G & IgAN
Creators: D Kavanagh - Royal Victoria Infirmary
A Alladin-Karan - University of Calgary
S Alexander - Christian Medical College, Vellore
S Chauvet - Hôpital Européen Georges-Pompidou
C K Cheung - University Hospitals of Leicester NHS Trust
H T Cook - Imperial College Healthcare NHS Trust
F Fakhouri - University of Lausanne
V Fremeaux-Bacchi - Hôpital Européen
D P Gale - University College London
P Garred - Copenhagen University Hospital
R A Lafayette - Stanford University
A L T Ma - University of Hong Kong
C Nester - University of Iowa Stead Family Children’s Hospital
R J H Smith - University of Iowa, Iowa Neuroscience Institute
E Pillebout - Inserm
H N Reich - University Health Network
D V Rizk - University of Alabama at Birmingham
I S D Roberts - John Radcliffe Hospital
B H Rovin - The Ohio State University Wexner Medical Center
S H Sacks - King's College London
S Shah - King's College London
H Trimarchi - Hospital Británico de Buenos Aires
M Vivarelli - Bambino Gesù Children's Hospital
E K S Wong - Royal Victoria Infirmary
H Zhang - Peking University
J Barratt - University of Leicester
Forum Participants
Resource Type: Journal article
Publication Details: Kidney international
DOI: 10.1016/j.kint.2026.08.007
PMID: 42648401
ISSN: 1523-1755
eISSN: 1523-1755
Publisher: Elsevier
Language: English
Electronic publication date: 08/26/2026
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Molecular Physiology and Biophysics; Anatomy and Cell Biology; Nephrology, Dialysis and Transplantation; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Otolaryngology; Internal Medicine
Record Identifier: 9985220839802771

Metrics

1 Record Views